Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer – Cancer Network
|
Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer
Cancer Network The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, … |
